Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Propylene glycol review

This article was originally published in The Rose Sheet

Executive Summary

Propylene glycol is of "negligible concern for reproductive or developmental toxicity in humans" at current estimated exposure levels, National Toxicology Program Center for the Evaluation of Risks to Human Reproduction Expert Panel concludes following Feb. 11-13 meeting in Alexandria, Va. Panel recommends collection of additional research to address some data gaps in humans and says one critical data need is long-term follow up of children and pregnant women exposed to high dose propylene glycol from continuous IV infusion via medical tubing. CERHR published a draft report on propylene glycol including some dermal absorption data in December (1"The Rose Sheet" Dec. 16, 2002, p. 9)...

You may also be interested in...



Propylene Glycol Dermal Absorption Data Included In CERHR Draft Report

Dermal absorption of propylene glycol across intact skin is likely to be slow, and any dermal exposure to the ingredient "will result in systematic levels far below saturation of metabolic clearance," according to a draft report by the National Toxicology Program Center for the Evaluation of Risks to Human Reproduction

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 
UsernamePublicRestriction

Register

RS011017

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel